Christopher Dente, OD
Optometrist · Bernardsville, NJNPI 1770598401
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.5%), food and beverage and education — rather than concentrated in one kind of arrangement. AbbVie accounts for 67.5% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2019 at $4,086 and has fallen 80.5% since, to $798 in 2025. Among optometrist clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 174 payments — averaging $43.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- Sight Sciences, Inc.$508
- Glaukos Corporation$407
- Eyevance Pharmaceuticals LLC$400
- Bausch & Lomb Americas Inc.$375
- Novartis$232
- plus $527 from 7 others
What the payments were for
- Speaking & faculty fees$3,80051%
- Food & beverage$3,64848%
- Education$761%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 89 | $5,075 |
| Sight Sciences, Inc. | 6 | $508 |
| Glaukos Corporation | 2 | $407 |
| Eyevance Pharmaceuticals LLC | 10 | $400 |
| Bausch & Lomb Americas Inc. | 18 | $375 |
| Novartis | 22 | $232 |
| Alcon | 7 | $213 |
| Johnson & Johnson Vision Care, Inc. | 8 | $143 |
| Sun Pharmaceutical Industries Inc. | 4 | $52 |
| Oyster Point Pharma, Inc. | 3 | $45 |
| Kala Pharmaceuticals, Inc. | 2 | $33 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $28 |
| Aerie Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LUMIGAN$4,045
- COMBIGAN$800
- OMNI(R) SURGICAL SYSTEM (US)$261
- Tobradex ST$242
- iDose$240
- OMNI$213
- TRYPTYR$123
- VYZULTA$120
How this compares
$7,524 in reported general payments places this provider in the 95th percentile of 1,357 optometrist providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 134 | $54,882 |
| RestasisCyclosporine | 37 | $39,692 |
| XiidraLifitegrast | 43 | $31,680 |
| VyzultaLatanoprostene Bunod | 83 | $28,136 |
| CombiganBrimonidine Tartrate/Timolol | 58 | $17,095 |
| MieboPerfluorohexyloctane/Pf | 18 | $13,605 |
| Cyclosporine | 13 | $7,364 |
| Alphagan PBrimonidine Tartrate | 35 | $7,257 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 39 | $6,655 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 14 | $3,791 |
| Latanoprost | 364 | $3,494 |
| Brimonidine Tartrate | 55 | $3,166 |
| Timolol Maleate | 72 | $2,151 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 70 | $1,423 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 29 | $1,172 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $5,075 | $118,926264 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $375 | $73,421144 claims |
| AlconSimbrinza | $213 | $3,79114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,357 optometrist providers in New Jersey.
Other optometrist in Bernardsville
- Kerry GelbWoodbridge$264K
- Rodolfo RodriguezNorth Bergen$244K
- Steven SorkinFairfield$146K
- Paul VaccarellaRockaway$99K
- Ada NohCinnaminson$74K
- Melanne RosettaIselin$66K
- Frank BuccieroSpringfield$57K
- Victoria DzurinkoDeptford$47K
- Michael McAleeseHowell$33K
- Gary RochaParamus$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.